Medtronic reported better-than-expected Q1 earnings and revenue, and subsequently raised its full-year 2027 adjusted EPS and organic revenue growth guidance. Despite the positive financial results and increased outlook, the company's shares experienced a slight dip in pre-market trading, possibly due to Q2 guidance midpoint falling below consensus.
Medtronic announced strong first-quarter results, surpassing analyst expectations for both earnings per share and revenue. This positive performance led the company to raise its fiscal 2027 adjusted EPS guidance and organic revenue growth forecast, indicating confidence in future growth. However, the stock saw a slight pre-market decline, potentially due to the second-quarter adjusted earnings midpoint falling below the consensus estimate, suggesting some near-term caution from investors. This creates a short-term opportunity for traders to assess if the market is overreacting to the Q2 guidance, given the overall positive long-term outlook and strategic partnership announcement with Cornerstone Robotics.